Low-cap pot: Small cannabis companies
23 No. of Symbols
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.030 CAD
−13.08 M CAD
33.06 M CAD
388.58 M
About MEDIPHARM LABS CORP
Sector
Industry
CEO
David A. Pidduck
Website
Headquarters
Barrie
Founded
2015
FIGI
BBG00K17KRQ8
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company focuses on the downstream secondary extraction methodology, distillation, and cannabinoid isolation and purification. It supplies raw materials, formulations, processing, and packaging for the creation of ready-to-sell derivative products. The company was founded by Patrick McCutcheon in 2015 and is headquartered in Barrie, Canada.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where LABS is featured.
Frequently Asked Questions
The current price of LABS is 0.065 CAD — it has decreased by −7.69% in the past 24 hours. Watch MEDIPHARM LABS CORP stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange MEDIPHARM LABS CORP stocks are traded under the ticker LABS.
LABS stock has fallen by −7.69% compared to the previous week, the month change is a −14.29% fall, over the last year there was no change in MEDIPHARM LABS CORP price.
LABS reached its all-time high on May 14, 2019 with the price of 7.390 CAD, and its all-time low was 0.055 CAD and was reached on Jun 27, 2023. View more price dynamics on LABS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
LABS stock is 8.33% volatile and has beta coefficient of 1.10. Track MEDIPHARM LABS CORP stock price on the chart and check out the list of the most volatile stocks — is MEDIPHARM LABS CORP there?
Today MEDIPHARM LABS CORP has the market capitalization of 26.72 M, it has decreased by −7.14% over the last week.
Yes, you can track MEDIPHARM LABS CORP financials in yearly and quarterly reports right on TradingView.
MEDIPHARM LABS CORP is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
LABS earnings for the last quarter are −0.01 CAD per share, whereas the estimation was 0.00 CAD resulting in a −212.50% surprise. The estimated earnings for the next quarter are 0.00 CAD per share. See more details about MEDIPHARM LABS CORP earnings.
MEDIPHARM LABS CORP revenue for the last quarter amounts to 9.80 M CAD, despite the estimated figure of 12.24 M CAD. In the next quarter, revenue is expected to reach 10.90 M CAD.
LABS net income for the last quarter is −2.77 M CAD, while the quarter before that showed −2.58 M CAD of net income which accounts for −7.39% change. Track more MEDIPHARM LABS CORP financial stats to get the full picture.
No, LABS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 166.00 employees. See our rating of the largest employees — is MEDIPHARM LABS CORP on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MEDIPHARM LABS CORP EBITDA is −8.77 M CAD, and current EBITDA margin is −49.46%. See more stats in MEDIPHARM LABS CORP financial statements.
Like other stocks, LABS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MEDIPHARM LABS CORP stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MEDIPHARM LABS CORP technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MEDIPHARM LABS CORP stock shows the sell signal. See more of MEDIPHARM LABS CORP technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.